Tentative OK for Basaglar; but not a biosimilar
This article was originally published in Scrip
Executive Summary
While the FDA granted a "tentative" approval on 18 August to Lilly’s and Boehringer Ingelheim's Basaglar (insulin glargine injection) in diabetes, the drug is far away from entering the US market due to pending litigation.